IP Library › Granted Patent US 12,564,590
Granted Patent B2
US 12,564,590 · App. 17/917,193 · Granted Mar 3, 2026

Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof

Inventors: Gerard M. McGeehan (Newtown Square, PA); Peter Ordentlich (Lexington, MA); Galit Rosen (Newton, MA); Steven A. Smith (San Jose, CA)
Assignee: Syndax Pharmaceuticals, Inc.
A61K31/506A61K31/496A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,564,590
App. No.
17/917,193
Granted
Mar 3, 2026
Kind
B2
Abstract

The present invention is directed to combinations of menin inhibitors with one or more CYP3A4 inhibitors, pharmaceutical compositions thereof, and methods of treating cancer and other diseases mediated by the menin-HLL interaction. Accordingly, the present disclosure provides compounds, e.g., of Formula (II), which inhibit menin and are useful in the treatment of diseases mediated by the menin-MLL interaction in combination with a strong CYP3A4 inhibitor.

Claims (35)

1 . A method of treating a leukemia in a human in need thereof comprising orally administering about 280-350 mg/day of a menin inhibitor of Formula (II),

and a strong CYP3A4 inhibitor.

2 . The method of claim 1 , wherein the strong CYP3A4 inhibitor is selected from the group consisting of boceprevir, nefazodone, clarithromycin, nelfinavir, conivaptan, posaconazole, grapefruit juice, ritonavir, indinavir, saquinavir, itraconazole, telaprevir, ketoconazole, telithromycin, lopinavir, voriconazole, cobicistat, and mibefradil.

3 . The method of claim 1 , wherein the strong CYP3A4 inhibitor is an azole antifungal.

4 . The method of claim 1 , wherein the menin inhibitor and the strong CYP3A4 inhibitor are in separate unit doses.

5 . The method of claim 1 , wherein the menin inhibitor and the strong CYP3A4 inhibitor are administered concurrently, sequentially, simultaneously, essentially simultaneously or within a treatment protocol.

6 . The method of claim 1 , comprising administering about 300-340 mg/day of the menin inhibitor of Formula (II).

7 . The method of claim 6 , comprising administering about 310 mg/day of the menin inhibitor of Formula (II).

8 . The method of claim 6 , comprising administering about 320 mg/day of the menin inhibitor of Formula (II).

9 . The method of claim 6 , comprising administering about 330 mg/day of the menin inhibitor of Formula (II).

10 . The method of claim 1 , wherein the 280-350 mg/day dosage is divided into multiple doses which are administered twice daily.

11 . The method of claim 10 , wherein the 320 mg/day dosage is divided into multiple doses which are administered twice daily.

12 . The method of claim 1 , wherein the leukemia is mixed lineage leukemia (MLL), MLL-related leukemia, MLL-associated leukemia, MLL-positive leukemia, MLL-induced leukemia, rearranged mixed lineage leukemia (MLL-r), leukemia associated with a MLL rearrangement or a rearrangement of the MLL gene, acute leukemia, chronic leukemia, indolent leukemia, lymphoblastic leukemia, lymphocytic leukemia, myeloid leukemia, myelogenous leukemia, childhood leukemia, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), acute granulocytic leukemia, acute nonlymphocytic leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), therapy related leukemia, myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), myeloproliferative neoplasia (MPN), plasma cell neoplasm, multiple myeloma, myelodysplasia, cutaneous T-cell lymphoma, lymphoid neoplasm, AIDS-related lymphoma, thymoma, thymic carcinoma, mycosis fungoides, Alibert-Bazin syndrome, granuloma fungoides, Sezary Syndrome, hairy cell leukemia, T-cell prolymphocytic leukemia (T-PLL), large granular lymphocytic leukemia, meningeal leukemia, leukemic leptomeningitis, leukemic meningitis, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma (malignant lymphoma), or Waldenstrom's macroglobulinemia.

13 . The method of claim 1 , wherein the leukemia is an acute leukemia.

14 . The method of claim 1 , wherein the leukemia is AML or ALL.

15 . The method of claim 1 , wherein the leukemia is a MLL-r leukemia.

16 . The method of claim 1 , wherein the leukemia is a nucleophosmin (NPM1)-mutated leukemia.

17 . The method of claim 1 , wherein the CYP3A4 inhibitor is selected from the group consisting of cobicistat, posaconazole, itraconazole, and voriconazole.

18 . The method of claim 1 , wherein the menin inhibitor of Formula (II) is administered as a pharmaceutically acceptable salt, solvate, and/or hydrate thereof.

19 . A method of treating an NPM1-mutated leukemia or a MLL-r leukemia in a human in need thereof comprising orally administering about 320 mg/day of a menin inhibitor of Formula (II),

wherein the menin inhibitor of Formula (II) is administered twice daily, and a strong CYP3A4 inhibitor.

20 . The method of claim 19 , wherein the strong CYP3A4 inhibitor is selected from the group consisting of boceprevir, nefazodone, clarithromycin, nelfinavir, conivaptan, posaconazole, grapefruit juice, ritonavir, indinavir, saquinavir, itraconazole, telaprevir, ketoconazole, telithromycin, lopinavir, voriconazole, cobicistat, and mibefradil.

21 . The method of claim 19 , wherein the strong CYP3A4 inhibitor is selected from the group consisting of cobicistat, posaconazole, itraconazole, and voriconazole.

22 . The method of claim 19 , wherein the strong CYP3A4 inhibitor is an azole antifungal.

23 . The method of claim 19 , wherein the menin inhibitor and the CYP3A4 inhibitor are in separate unit doses.

24 . The method of claim 19 , wherein the menin inhibitor and the strong CYP3A4 inhibitor are administered simultaneously.

25 . The method of claim 19 , wherein the menin inhibitor of Formula (II) is administered as a pharmaceutically acceptable salt, solvate, and/or hydrate thereof.

26 . A method of treating an ALL or AML in a human in need thereof comprising orally administering about 320 mg/day of a menin inhibitor of Formula (II),

and a strong CYP3A4 inhibitor.

27 . The method of claim 26 , wherein the strong CYP3A4 inhibitor is selected from the group consisting of boceprevir, nefazodone, clarithromycin, nelfinavir, conivaptan, posaconazole, grapefruit juice, ritonavir, indinavir, saquinavir, itraconazole, telaprevir, ketoconazole, telithromycin, lopinavir, voriconazole, cobicistat, and mibefradil.

28 . The method of claim 26 , wherein the strong CYP3A4 inhibitor is an azole antifungal.

29 . The method of claim 26 , wherein the menin inhibitor and the strong CYP3A4 inhibitor are in separate unit doses.

30 . The method of claim 26 , wherein the menin inhibitor of Formula (II) and the strong CYP3A4 inhibitor are administered concurrently, sequentially, simultaneously, essentially simultaneously or within the same treatment protocol.

31 . The method of claim 26 , wherein the 320 mg/day dosage of Formula (II) is divided into multiple doses which are administered twice daily.

32 . The method of claim 26 , wherein the strong CYP3A4 inhibitor is selected from the group consisting of cobicistat, posaconazole, itraconazole, and voriconazole.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2022
From: MCGEEHAN, GERARD M.; ORDENTLICH, PETER; ROSEN, GALIT; SMITH, STEVEN A.
To: SYNDAX PHARMACEUTICALS, INC.
Reel/Frame 061997/0087 →
Continuity (2)
Provisional Application 63006574 · Apr 7, 2020
Related Publication 20230165858A1 · Jun 1, 2023
References Cited (132)
US 5292740A · Burri et al. · 1994 [cited by applicant]
US 5820915A · Harris · 1998 [cited by applicant]
US 5990154A · Harris · 1999 [cited by applicant]
US 5993887A · Harris · 1999 [cited by applicant]
US 6054477A · Harris · 2000 [cited by applicant]
US 6063809A · Harris · 2000 [cited by applicant]
US 6124477A · Harris · 2000 [cited by applicant]
US 6162479A · Harris · 2000 [cited by applicant]
US 6248776B1 · Harris · 2001 [cited by applicant]
US 6255337B1 · Harris · 2001 [cited by applicant]
US 6309687B1 · Harris · 2001 [cited by applicant]
US 6476066B1 · Harris · 2002 [cited by applicant]
US 6660766B2 · Harris · 2003 [cited by applicant]
US 9101622B2 · Zeldis · 2015 [cited by applicant]
US 9969727B2 · Le et al. · 2018 [cited by applicant]
US 10683302B2 · Cacatian et al. · 2020 [cited by applicant]
US 10752639B2 · Wu et al. · 2020 [cited by applicant]
US 10869868B2 · Armstrong · 2020 [cited by applicant]
US 11479557B2 · Cacatian et al. · 2022 [cited by applicant]
US 12312359B2 · Cacatian et al. · 2025 [cited by applicant]
US 20040058982A1 · Harris · 2004 [cited by applicant]
US 20050209301A1 · Eissenstat et al. · 2005 [cited by applicant]
US 20050267074A1 · Eissenstat et al. · 2005 [cited by applicant]
US 20130102525A1 · Bernstein et al. · 2013 [cited by applicant]
US 20140309427A1 · Dutta · 2014 [cited by applicant]
US 20150329535A1 · Sole Feu et al. · 2015 [cited by applicant]
US 20160339035A1 · Berger et al. · 2016 [cited by applicant]
US 20180125839A1 · Jain · 2018 [cited by applicant]
US 20180243303A1 · Grembecka et al. · 2018 [cited by applicant]
US 20190076540A1 · Phillips et al. · 2019 [cited by applicant]
US 20190144459A1 · Cacatian et al. · 2019 [cited by applicant]
US 20190307750A1 · Armstrong · 2019 [cited by applicant]
US 20200223853A1 · Butler et al. · 2020 [cited by applicant]
US 20210115018A1 · Wang et al. · 2021 [cited by applicant]
US 20210317214A1 · Chartash et al. · 2021 [cited by applicant]
US 20240238291A1 · Mcgeehan et al. · 2024 [cited by applicant]
US 20240400564A1 · Cacatian et al. · 2024 [cited by applicant]
US 20250041299A1 · Armstrong et al. · 2025 [cited by applicant]
CN 105732636A · 2016 [cited by applicant]
JP 2014517016A · 2014 [cited by applicant]
JP 2018538330A · 2018 [cited by applicant]
WO WO0054768A1 · 2000 [cited by applicant]
WO WO2004037827A1 · 2004 [cited by applicant]
WO WO2009137733A1 · 2009 [cited by applicant]
WO WO2012170976A2 · 2012 [cited by applicant]
WO WO2014164543A1 · 2014 [cited by applicant]
WO WO2015191701A1 · 2015 [cited by applicant]
WO WO2017112768A1 · 2017 [cited by applicant]
WO WO2017192543A1 · 2017 [cited by applicant]
WO WO2017214367A1 · 2017 [cited by examiner]
WO WO2018053267A1 · 2018 [cited by applicant]
WO WO2018175746A1 · 2018 [cited by applicant]
WO WO2019120209A1 · 2019 [cited by applicant]
WO WO2019143977A1 · 2019 [cited by applicant]
WO WO2020069027A1 · 2020 [cited by applicant]
WO WO2021207335A1 · 2021 [cited by applicant]
WO WO2022241122A1 · 2022 [cited by applicant]
WO WO2022241265A1 · 2022 [cited by applicant]
WO WO2023018825A1 · 2023 [cited by applicant]
WO WO2023114867A2 · 2023 [cited by applicant]
WO WO2025049521A1 · 2025 [cited by applicant]
Cecil Textbook of Medicine, 20th Ed., vol. 1 (Year: 1997). [cited by examiner]
Wu et al., Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021; Journal of Hematology & Oncology, 15, 143 (Year: 2022). [cited by examiner]
Pounds et al., “Repurposing itraconazole for the treatment of cancer (Review)”, Oncology Letters, 2587-2597 (Year: 2017). [cited by examiner]
Baell et al., “Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth,” Nature 560(7717):253-257 (2018). [cited by applicant]
CAS Registry No. 180-43-8; Spiro[5.5]undecane, STN Entry Date: Nov. 16, 1984; 1 page. [cited by applicant]
CAS Registry No. 236406-49-8; Tert-butyl 2,7-diazaspiro [4.4]nonane-2-carboxylate, STN Entry Date: Sep. 1, 1999; 3 pages. [cited by applicant]
Clinical Trial NCT02141828: A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients with Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene, First Posted… [cited by applicant]
Clinical Trial NCT04065399: A Study of SNDX-5613 in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101), First Posted in 2019, 8 pages. [cited by applicant]
Clinical Trial NCT04067336: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia, First Posted in 2019, 6 pages. [cited by applicant]
Clinical Trial NCT04606446: Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6), First Posted in 2020, 8 pages. [cited by applicant]
Clinical Trial NCT04752163: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia, First Posted in 2021, 16 pag… [cited by applicant]
Clinical Trial NCT04811560: A Study of JNJ-75276617 in Participants with Acute Leukemia, First Posted in 2021, 5 pages. [cited by applicant]
Clinical Trial NCT04988555: A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation, First Posted in 2021, 7 pages. [cited by applicant]
Dafflon, C., et al.; “Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia,” Leukemia (2017); 31(6):1269-1277. [cited by applicant]
Daigle, S.R. et al. (2011) “Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor” Cancer Cell, 20(1):53-65. [cited by applicant]
Dinardo C., et al., “Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies,” American journal of hematology, 20… [cited by applicant]
Fiskus et al., “Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c),” Blood Cancer J. (2022); 12(1):5, 11 pages. [cited by applicant]
Godamudunage, M.P., et al.; “Comparison of Antifungal Azole Interactions with Adult Cytochrome P450 3A4 versus Neonatal Cytochrome P450 3A7,” Drug Metab Dispos. (2018); 46(9):1329-1337. [cited by applicant]
Hemming, M.L., et al.; “Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition,” Cancer Res., (2019); 79(5):994-1009. [cited by applicant]
Hemming, M.L., et al.; “Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome,” Proc Natl Acad Sci USA, (2018); 115(25):E5746-E5755. [cited by applicant]
Hemming, M.L., et al.; “Proteomic Profiling of γ-Secretase Substrates and Mapping of Substrate Requirements,” PLoS Biol. (2008); 6(10): e257:2314-2328. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/029271 mailed on Nov. 23, 2023, 8 pages. [cited by applicant]
Kerry J., et al., “MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia,” Cell reports , 2017, vol. 18(2), pp. 482-495. [cited by applicant]
Klossowski, S., et al.; “Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia,” J Clin Invest., (2020); 130(2):981-997. [cited by applicant]
Krivtsov, A.V., et al.; “A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia,” Cancer Cell (2019); 36(6):660-673.e11, 26 pages. [cited by applicant]
Le Gall, M., et al.; “Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5,” Mol Cancer Ther., (2015); 14(11):2595-2605. [cited by applicant]
Maki, R.G., et al.; “Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: an Expert Discussion,” Oncologist. (2015); 20(7):823-830. [cited by applicant]
McGeehan et al., “A first-in-class Menin-MLL1 antagonist for the treatment of MLL-r and NPM1 mutant leukemias,” Syndax Pharmaceuticals, Inc., AACR Virtual Annual Meeting, Apr. 27, 2020, retrieved online: https://www.onc… [cited by applicant]
Medchemexpress, SNDX-5613, 2022, [Retrieved online Sep. 18, 2023] URL: https://web.archive.org/web/20220308174847/https://www.medchemexpress.com/sndx-5613.html; 3 pages. [cited by applicant]
Paggetti, J., et al.; “Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells,” Oncogene. (2010); 29(36):5019-5031. [cited by applicant]
Shi, X., et al.; “Distinct cellular properties of oncogenic KIT receptor tyrosine kinase mutants enable alternative courses of cancer cell inhibition,” Proc Natl Acad Sci USA (2016); 113(33):E4784-4793. [cited by applicant]
Uckelmann, H.J., et al.; “Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia,” Science (2020); 367(6477):586-590, 6 pages. [cited by applicant]
Xu, S.X., et al.; “Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong In Vivo Antitumor Activity,” J Med Chem. (2020); 63(9):4997-5010. [cited by applicant]
Yang, L., et al.; “Histone H3K4 Methyltransferases as Targets for Drug-Resistant Cancers,” Biology (Basel). (2021); 10(7):581, pp. 1-32. [cited by applicant]
Borkin et al. “Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo”, Cancer Cell, vol. 27, p. 589-602 (2015). [cited by applicant]
Chamberlain et al. “Menin determines K-RAS proliferative outputs in endocrine cells”, The Journal of Clinical Investigation, vol. 124, No. 9, p. 4093-4101 (2014). [cited by applicant]
Cierpicki T. et al. “Challenges and opportunities in targeting the menin-MLL interaction”, Future Med. Chem. vol. 6, No. 4, p. 447-462 (2014). [cited by applicant]
Database STN, CAS Registry No. 1048962-49-7 “3-Oxabicyclo[3.1.0]hexan-6-amine, hydrochloride (1:1), (1α,5α,6α)—(CA Index Name)”, Chemical Abstracts Service, American Chemical Society entered Sep. 12, 2008; retrieved Apr… [cited by applicant]
Database STN, CAS Registry No. 58564-87-7 “7-Oxabicyclo[2.2.1]heptan-2-amine, (1R,2R,4S)-rel—(CA Index Name)”, Chemical Abstracts Service, American Chemical Society entered Nov. 16, 1984; retrieved Apr. 18, 2023; 1 page. [cited by applicant]
Freedman et al., “Non-Hodgkin's Lymphomas” Chapter 134, Cancer Medicine, American Cancer Society, B.C. Decker Inc., Hamilton, Ontario, (2003), 30 pages. [cited by applicant]
Grembecka J. et al. “Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia”, Nature Chemical Biology, vol. 8, p. 277-284 (2012). [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2021/026141 dated Oct. 20, 2022, 7 pages. [cited by applicant]
International Preliminary Report on Patentability of International Application No. PCT/US2017/036506, issued Dec. 11, 2018, 6 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/029271, mailed Aug. 2, 2022, 10 pages. [cited by applicant]
International Search Report and Written Opinion of International Application No. PCT/US2017/036506, mailed on Sep. 11, 2017, 9 pages. [cited by applicant]
International Search Report and Written Opinion of International Application No. PCT/US2021/026141, mailed Jun. 30, 2021, 8 pages. [cited by applicant]
Jagtap et al. “Synthesis of (R)-3, 4-dihydro-2H-pyran-2-carboxaldehyde: application to the synthesis of potent adenosine A2A and A3 receptor agonist”, Tetrahedron Letters, (2009); 50(22):2693-2696. [cited by applicant]
Kang et al. “Enzymatic synthesis of optically active (S)-(+)-2-hydroxymethyl-3, 4-dihydro-2H-pyran and (S)-(+)-2-acetoxymethyl-3, 4-dihydro-2H-pyran”, Tetrahedron: Asymmetry, (1995); 6(1):97-100. [cited by applicant]
Karageorgis et al. “Activity-Directed Synthesis with Intermolecular Reactions: Development of a Fragment into a Range of Androgen Receptor Agonists”, Angewandte Chemie, International Edition, (2015); 54(46): 13538-13544. [cited by applicant]
Kress et al. “Chemistry of Pyrimidine. 2. Synthesis of Pyrimidine JV-Oxides and 4-Pyrimidinones by Reaction of 5-Substituted Pyrimidines with Peracids. Evidence for Covalent Hydrates as Reaction Intermediates”, J. Org. … [cited by applicant]
Maiti D. et al. “Cu-Catalyzed Arylation of Phenols: Synthesis of Sterically Hindered and Heteroaryl Diaryl Ethers”, J. Org. Chem. vol. 75, p. 1791-1794 (2010). [cited by applicant]
Malik R. et al. “Targeting the MLL complex in castration-resistant prostate cancer”, Nature Medicine, vol. 21, No. 4, p. 344-354 (2015). [cited by applicant]
Salvi L. et al. “A New Biarylphosphine Ligand for the Pd-Catalyzed Synthesis of Diaryl Ethers under Mild Conditions”, Organic Letters, vol. 14, No. 1, p. 170-173 (2012). [cited by applicant]
Shi, A., et al., “Structural Insights into Inhibition of the Bivalent Menin-MLL Interaction by Small Molecules in Leukemia”, Blood, vol. 120(23), pp. 4461-4469. [cited by applicant]
Yang Y. et al. “Reversal of preexisting hyperglycemia in diabetic mice by acute deletion of the Men1 gene”, PNAS, vol. 107, No. 47, p. 20358-20363 (2010). [cited by applicant]
Yokoyama A. et al. “The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis”, Cell, vol. 123, p. 207-218, (2005). [cited by applicant]
Zhang et al. “Design, synthesis, and preliminary SAR study of 3-and 6-side-chain-extended tetrahydro-pyran analogues of cis-and trans-(6-benzhydryl-tetrahydropyran-3-yl)-benzylamine”, Bioorganic & Medicinal Chemistry, (… [cited by applicant]
Arnold et al. “Traditional and emerging antifungal therapies” Proceedings of the American Thoracic Society (2010); 7(3):222-228. [cited by applicant]
Berge et al. “Pharmaceutical salts” Journal of Pharmaceutical Sciences (1977); 66(1):1-19. [cited by applicant]
Carter et al. “Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML” Blood, The Journal of the American Society of Hematology (2021); 138(17):1637-1641. [cited by applicant]
Issa et al. “Therapeutic implications of menin inhibition in acute leukemias” Leukemia (2021); 35(9):2482-2495. [cited by applicant]
JP Office Action for JP Application No. 2022-561040 mailed Apr. 3, 2025, with English Translation, 13 pages. [cited by applicant]
Kumar et al. “An overview of automated systems relevant in pharmaceutical salt screening” Drug Discovery Today (2007); 12(23-24):1046-1053. [cited by applicant]
Li et al. “Selective killing of cancer cells by β-lapachone: Direct checkpoint activation as a strategy against cancer” Proceedings of the National Academy of Sciences (2003); 100(5):2674-2678. [cited by applicant]
Miao et al. “Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations” Blood, The Journal of the American Society of Hematology (2020); 136(25):2958-… [cited by applicant]
Miettinen et al. “A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia” Cancer (2007); 112(3):645-649. [cited by applicant]
Mu et al. “Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours” J. Cell Mol Med. (2020); 24(4):2519-2530, 12 pages. [cited by applicant]
Patel et al. “NPM1 biology in myeloid neoplasia” Current Hematologic Malignancy Reports (2020); 15(4):350-359. [cited by applicant]
Revuforj (revumenib), tablets for oral use, 25 mg, 110 mg, 160 mg, Highlights of Prescribing Information / Package Insert / Label, Revised: Nov. 2024 (Nov. 2024), Initial U.S. Approval: 2024, Reference ID: 5479801, Manu… [cited by applicant]
Shi, et al. “Menin-MLL1 Interaction Small Molecule Inhibitors: a Potential Therapeutic Strategy for Leukemia and Cancers” Molecules (2023); 28(7):3026, 15 pages. [cited by applicant]
Zanger et al., “Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation”, [cited by applicant]